ConductScience.org, home

Paper38879802

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Bumma N and 31 others. J Clin Oncol, 2024. Cited by 165 papers, by iCite.

Cite this record

ConductScience Library. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Papers, record 38879802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38879802

Download JSON
Disease
plasma cell myeloma553 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
PubMed
Journal
J Clin Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
165
iCite
Relative citation ratio, by iCite
21.79, provisional
iCite
Revised in PubMed
2026-06-11
PubMed

Authors32

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bumma NNaresh
2Richter JJoshuahttps://orcid.org/0000-0002-0274-0585
3Jagannath SSundarhttps://orcid.org/0000-0003-2934-6518
4Lee HCHans Chttps://orcid.org/0000-0001-8545-3292
5Hoffman JEJames E
6Suvannasankha AAttayahttps://orcid.org/0000-0001-9445-8781
7Zonder JAJeffrey Ahttps://orcid.org/0000-0002-1741-2795
8Shah MRMansi Rhttps://orcid.org/0000-0001-8884-3085
9Lentzsch SSuzannehttps://orcid.org/0000-0003-1708-7344
10Baz RRachidhttps://orcid.org/0000-0003-4538-4733
11Maly JJJoseph J
12Namburi SSwathi
13Pianko MJMatthew Jhttps://orcid.org/0000-0001-9295-9750
14Ye JCJing Christine
15Wu KLKa Lunghttps://orcid.org/0000-0001-6042-978X
16Silbermann RRebeccahttps://orcid.org/0000-0002-7571-1523
17Min CKChang-Ki
18Vekemans MCMarie-Christiane
19Munder MMarkushttps://orcid.org/0000-0003-4947-8796
20Byun JMJa Minhttps://orcid.org/0000-0003-1780-5553

Source PubMed

See all 32 authorsDownload CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Antibodies, BispecificMajor topic
Humans
Aged
Male
Female
Middle Aged
Aged, 80 and over
B-Cell Maturation Antigen
Adult
Neoplasm Recurrence, Local

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03761108Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in39405492Erratum: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.https://conductscience.org/library/papers/39405492

Source PubMed

Download CSV of comments and corrections

Cited by110

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 165 citations.

PMIDTitleJournalYearIn PapersSource
42982775Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma.Blood Cancer J2026https://conductscience.org/library/papers/42982775PubMed
42980050Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions.Cancer2026https://conductscience.org/library/papers/42980050PubMed
42959251Rethinking immunotherapy sequencing in multiple myeloma: a conceptual adaptive immunotherapy sequencing model.Front Immunol2026https://conductscience.org/library/papers/42959251PubMed
42921550Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations.Drug Des Devel Ther2026https://conductscience.org/library/papers/42921550PubMed
42882842Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies.Cancers (Basel)2026https://conductscience.org/library/papers/42882842PubMed
42871283Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies.Front Immunol2026https://conductscience.org/library/papers/42871283PubMed
42846987Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.Hemasphere2026https://conductscience.org/library/papers/42846987PubMed
42844619T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.J Hematol Oncol2026https://conductscience.org/library/papers/42844619PubMed
42827135Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study.Blood Cancer J2026https://conductscience.org/library/papers/42827135PubMed
42809698T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity.Cancer J2026https://conductscience.org/library/papers/42809698PubMed
42786443Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.BMC Cancer2026https://conductscience.org/library/papers/42786443PubMed
42718550Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42718550PubMed
42699035From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes.Ther Adv Hematol2026https://conductscience.org/library/papers/42699035PubMed
42686747T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42686747PubMed
42662238CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.Mol Ther Adv2026https://conductscience.org/library/papers/42662238PubMed
42653183T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.Int J Mol Sci2026https://conductscience.org/library/papers/42653183PubMed
42643454Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.Front Immunol2026https://conductscience.org/library/papers/42643454PubMed
42632850Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.Blood Cancer J2026https://conductscience.org/library/papers/42632850PubMed
42614483Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies.Open Forum Infect Dis2026https://conductscience.org/library/papers/42614483PubMed
42592361From T cell engagers to next-generation immune cell engagers for cancer immunotherapy.Antib Ther2026https://conductscience.org/library/papers/42592361PubMed

See all 110 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
SEMA4D10507PubTator's text mininghttps://conductscience.org/library/genes/10507NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
LINVOSELTAMABCHEMBL5095373Derived from the trial1https://conductscience.org/library/drugs/CHEMBL5095373

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38879802

GET https://conductscience.org/api/papers/v1/38879802/authors?page=2